Wednesday, 29 July 2015

US Meningococcal Vaccines Drug Forecast and Market Analysis to 2022

GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines US Drug Forecast and Market Analysis to 2022”. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment.

To Browse a Full Report with TOC: http://www.researchmoz.us/pharmapoint-meningococcal-vaccines-united-states-drug-forecast-and-market-analysis-to-2022-report.html

GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

GlobalData expects the MenACWY patient share to remain stagnant because of the market’s high level of maturity. In contrast, the MenB vaccine market appears poised to take off in the US. GlobalData anticipates that Pfizer will target adolescents with its MenB vaccine, an approach that should facilitate rapid uptake, given the ACIP’s current immunization recommendations (CDC, 2013b). On the other hand, the reluctance of policymakers to implement a routine infant program that does not offer serogroup B protection poses a challenge to companies that have targeted this age segment, such as GSK.

Scope

Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in the US from 2012-2022.

Analysis of the impact of key events as well the drivers and restraints affecting the US Meningococcal Vaccines market.

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=170311

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of drug performance

Obtain sales forecast for drugs from 2012-2022 in the US

1 Table of Contents 4

1.1 List of Tables 7

1.2 List of Figures 8

2 Introduction 9

2.1 Catalyst 9

2.2 Related Reports 10

3 Disease Overview 12

3.1 Etiology and Pathophysiology 12

3.1.1 Etiology 12

3.1.2 Pathophysiology 14

3.2 Symptoms 15

3.3 Prognosis 16

4 Disease Management 17

4.1 Meningococcal Immunization Policy 18

4.2 US 20

4.2.1 Meningococcal Immunization Recommendations and Policies 20

4.2.2 Clinical Practice 22

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=170311

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Thailand Medical Equipment Manufacturers - Industry Report

Plimsoll Publishing’s Medical Equipment Manufacturers (Thailand) Analysis provides a detailed overview of the Medical Equipment Manufacturers (Thailand) market and delivers a comprehensive individual analysis on the top 50 companies, including RINCHOKECHAI CO LTD, TEGO DENTAL & CHEMICAL CO LTD and THAI ORCHID ELECTRONICS CO LTD.

To Browse a Full Report with TOC: http://www.researchmoz.us/medical-equipment-manufacturers-thailand-industry-report-report.html

This report (compiled in English language) includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest Medical Equipment Manufacturers (Thailand) analysis is ideal for anyone wanting to:

See the market leaders

Identify companies heading for failure

Seek out the most attractive acquisition

Analyse industry trends

Benchmark their own financial performance

Using Plimsoll’s exclusive methodology, a quick glance of this Medical Equipment Manufacturers (Thailand) report will tell you that 6 companies have a declining Plimsoll financial rating, while 10 have shown good sales growth.

Each of the largest 50 companies is meticulously scrutinised in a one-page individual assessment and is analysed using the most up-to-date and current financial data.

Every business is examined on the following features:

The Plimsoll Chart: A graphical assessment of a company’s financial performance

Four year assessment of the profit/loss and balance sheet

A written summary highlighting key performance issues

Subsequently, you will receive a thorough market analysis highlighting the latest changes in the Medical Equipment Manufacturers (Thailand) market.

This section includes:

Best Trading Partners

Sales Growth Analysis

Profit Analysis

Market Size

Rankings

Established in 1987, Plimsoll provides busy managers with a set of tools to monitor the financial welfare of their company, their rivals, or those they wish to acquire. The reports are used to assess the attractiveness of potential acquisitions, gain better understanding of a market and identify sound companies with whom to trade.

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=187204

TABLE OF CONTENT

Plimsoll’s Medical Equipment Manufacturers (Thailand) analysis is the most definitive and accurate study of the Medical Equipment Manufacturers (Thailand) sector in 2013.The report (compiled in English language) is split into two sections and uses both a written and graphical analysis – analysing the 50 largest Medical Equipment Manufacturers (Thailand) companies.

The Medical Equipment Manufacturers (Thailand) report contains the most-up-to-date financial data and Plimsoll applies these figures to create their unique and authoritative analysis.

Indeed, the first section thoroughly scrutinises the market and this section includes the following:

Best Trading Partners: These are companies that are winning in both sales and financial strength – for example INHOUSE DENTAL ART CO LTD has been ranked as a best trading partner in the industry.

Sales Growth Analysis: This section reviews the fastest growing and fastest shrinking company – for example SUMMIT HEALTHCARE CO LTD is among the fastest growing.

Profit Analysis – Analysis of gross profit and pre-tax profit over the last ten years and a profitability summary comparing profits in the industry against small, medium and large companies.

Market Size: Based on the largest 50 companies, this is a comparison between last year's market size and the most current figure.

Rankings: The top 50 companies ranked by: Market Share, Sales Growth, Gross Profit and Pre-tax Profit.

The next section focuses on company analysis and provides an in-depth analysis of the largest companies within the Medical Equipment Manufacturers (Thailand) industry.

Each business is analysed using Plimsoll’s unequivocal model and culminates in the production of the Plimsoll Chart. The Plimsoll Model uses a series of charts to graphically analyse an individual company and measure its ability to achieve sales growth while maintaining financial strength.

The Plimsoll Chart is a quick and dependable method of analysing a company’s financial well-being. It’s simple to understand: a rising line is good news and a falling line is bad news.

Therefore, this company analysis will tell you if a company is:

Strong or heading for failure

Utilising their investments

Becoming burdened by debt

Getting the most from their resources

The Plimsoll Medical Equipment Manufacturers (Thailand) analysis also provides you with full business name and address, name and ages of directors and registration address.

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=187204

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Spain Meningococcal Vaccines Drug Forecast and Market Analysis to 2022

GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines Spain Drug Forecast and Market Analysis to 2022”. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

To Browse a Full Report with TOC: http://www.researchmoz.us/pharmapoint-meningococcal-vaccines-spain-drug-forecast-and-market-analysis-to-2022-report.html

GlobalData predicts that relative patient share for the three MenC conjugate vaccines will remain unchanged for the duration of the forecast period because Nuron Biotech’s Meningitec, Novartis’ Menjugate kit, and Baxter’s NeisVac-C possess nearly identical clinical profiles and price points. The MenC conjugate patient share is largely determined by prescriber preference in Spain and therefore is not expected to change drastically during the forecast period. In addition, GlobalData believes that an expected change in the booster administration age, from two to 11 years of age, will not dramatically alter sales, although a small coverage rate decrease associated with the older age group may occur (MSSSI, 2013).

Scope

Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in Spain from 2012-2022.

Analysis of the impact of key events as well the drivers and restraints affecting Spain Meningococcal Vaccines market.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of drug performance

Obtain sales forecast for drugs from 2012-2022 in Spain

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=170315

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Nimenrix (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

To Browse a Full Report with TOC: http://www.researchmoz.us/nimenrix-meningococcal-vaccines-forecast-and-market-analysis-to-2022-report.html

Nimenrix (Meningococcal groups A, C, Y, W-135 polysaccharide tetanus toxoid conjugate vaccine) is the brand name for GSK’s tetravalent conjugate vaccine sold in the EU to protect children, adolescents, and adults against four serogroups of N. meningitidis (A, C, Y, W-135) that cause invasive meningococcal infections. Approved in the EU 2012, Nimenrix is the first tetravalent conjugate vaccine available in Europe for patients between 12 and 23 months of age.

Scope

Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on Nimenrix including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Nimenrix for the top nine countries from 2012 to 2022.

Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of Nimenrix performance

Obtain sales forecast for Nimenrix from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 8

2.1 Catalyst 8

2.2 Related Reports 9

3 Disease Overview 11

3.1 Etiology and Pathophysiology 12

3.1.1 Etiology 12

3.1.2 Pathophysiology 14

3.2 Symptoms 16

3.3 Prognosis 17

4 Disease Management 18

4.1 Meningococcal Immunization Policy 19

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=171849

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

NeisVac-C (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

To Browse a Full Report with TOC: http://www.researchmoz.us/neisvac-c-meningococcal-vaccines-forecast-and-market-analysis-to-2022-report.html

NeisVac-C (Meningococcal Serogroup C-TT Conjugate Vaccine, Adsorbed) is the brand name for Baxter’s MenC conjugate vaccine sold in the EU and Australia. First approved in the UK in 2000, NeisVac-C is one of the first meningococcal conjugate vaccines to be used in active immunization against meningococcal meningitis, specifically MenC.

Scope

Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on NeisVac-C including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for NeisVac-C for the top nine countries from 2012 to 2022.

Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of NeisVac-C performance

Obtain sales forecast for NeisVac-C from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 8

2.1 Catalyst 8

2.2 Related Reports 9

3 Disease Overview 11

3.1 Etiology and Pathophysiology 11

3.1.1 Etiology 11

3.1.2 Pathophysiology 13

3.2 Symptoms 14

3.3 Prognosis 15

4 Disease Management 16

4.1 Meningococcal Immunization Policy 17

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=171853

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

MnB rLP2086 (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

To Browse a Full Report with TOC: http://www.researchmoz.us/mnb-rlp2086-meningococcal-vaccines-forecast-and-market-analysis-to-2022-report.html

MnB rLP2086 is Pfizer’s recombinant protein vaccine that protects against MenB disease. Despite Pfizer’s position as a major player in the vaccine industry, MnB rLP2086 is currently the only meningococcal vaccine in the pharmaceutical giant’s portfolio. Originally developed by Wyeth, Pfizer acquired MnB rLP2086 with its purchase of the company in 2009. MnB rLP2086 is a bivalent vaccine composed of two variants of the N. meningitidis OMP LP2086, A05, and B01. LP086 is a lipoprotein (LP) linked to the outer membrane of the bacteria and promotes in vivo survival by binding Factor H and facilitating complement evasion.

Scope

Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on MnB rLP2086 including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for MnB rLP2086 for the top nine countries from 2012 to 2022.

Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of MnB rLP2086 performance

Obtain sales forecast for MnB rLP2086 from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 6

2 Introduction 7

2.1 Catalyst 7

2.2 Related Reports 8

3 Disease Overview 10

3.1 Etiology and Pathophysiology 10

3.1.1 Etiology 10

3.1.2 Pathophysiology 12

3.2 Symptoms 13

3.3 Prognosis 14

4 Disease Management 15

4.1 Meningococcal Immunization Policy 16

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=171856

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Menveo (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

To Browse a Full Report with TOC: http://www.researchmoz.us/menveo-meningococcal-vaccines-forecast-and-market-analysis-to-2022-report.html

Menveo (Meningococcal groups A, C, Y, W-135 oligosaccharide diphtheria CRM197 conjugate vaccine) is Novartis’ tetravalent conjugate vaccine licensed in the US, EU, Australia, and Brazil to protect against four serogroups of N. meningitidis (A, C, Y, W-135) that cause meningococcal disease in children, adolescents, and adults. Approved in 2010 for all markets in this report, Menveo was the second tetravalent conjugate vaccine to enter the market in US and Australia and the first to enter the 5EU markets.

Scope

Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on Menveo including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Menveo for the top nine countries from 2012 to 2022.

Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of Menveo performance

Obtain sales forecast for Menveo from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 8

2.1 Catalyst 8

2.2 Related Reports 9

3 Disease Overview 11

3.1 Etiology and Pathophysiology 12

3.1.1 Etiology 12

3.1.2 Pathophysiology 14

3.2 Symptoms 16

3.3 Prognosis 17

4 Disease Management 18

4.1 Meningococcal Immunization Policy 19

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=171848

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074